Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.
Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
Published results have updated preliminary findings presented at a previous conference.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
Writer Anna Forbes responds to an open letter by HIV researcher David Alain Wohl, MD, that urges AIDS activists to do more.
HIV researcher David Alain Wohl, MD, urges AIDS activists to be a vanguard against indifference, overreach and shortsightedness.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.